These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 21245938)

  • 1. Augmented osteolysis in SPARC-deficient mice with bone-residing prostate cancer.
    McCabe NP; Kerr BA; Madajka M; Vasanji A; Byzova TV
    Neoplasia; 2011 Jan; 13(1):31-9. PubMed ID: 21245938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraosseous injection of RM1 murine prostate cancer cells promotes rapid osteolysis and periosteal bone deposition.
    McCabe NP; Madajka M; Vasanji A; Byzova TV
    Clin Exp Metastasis; 2008; 25(5):581-90. PubMed ID: 18506587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secreted Protein Acidic and Rich in Cysteine (SPARC) Mediates Metastatic Dormancy of Prostate Cancer in Bone.
    Sharma S; Xing F; Liu Y; Wu K; Said N; Pochampally R; Shiozawa Y; Lin HK; Balaji KC; Watabe K
    J Biol Chem; 2016 Sep; 291(37):19351-63. PubMed ID: 27422817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The MET/Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted Tyrosine Kinase Inhibitor Also Attenuates FMS-dependent Osteoclast Differentiation and Bone Destruction Induced by Prostate Cancer.
    Watanabe K; Hirata M; Tominari T; Matsumoto C; Fujita H; Yonekura K; Murphy G; Nagase H; Miyaura C; Inada M
    J Biol Chem; 2016 Sep; 291(40):20891-20899. PubMed ID: 27539855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of cellular mechanisms of tumor osteolysis.
    Clohisy DR; Perkins SL; Ramnaraine ML
    Clin Orthop Relat Res; 2000 Apr; (373):104-14. PubMed ID: 10810467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human breast cancer induces osteoclast activation and increases the number of osteoclasts at sites of tumor osteolysis.
    Clohisy DR; Palkert D; Ramnaraine ML; Pekurovsky I; Oursler MJ
    J Orthop Res; 1996 May; 14(3):396-402. PubMed ID: 8676252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular pathway for cancer metastasis to bone.
    De S; Chen J; Narizhneva NV; Heston W; Brainard J; Sage EH; Byzova TV
    J Biol Chem; 2003 Oct; 278(40):39044-50. PubMed ID: 12885781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of osteoclastic activity in prostate cancer skeletal metastases.
    Keller ET
    Drugs Today (Barc); 2002 Feb; 38(2):91-102. PubMed ID: 12532187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Micro-CT combined with bioluminescence imaging: a dynamic approach to detect early tumor-bone interaction in a tumor osteolysis murine model.
    Fritz V; Louis-Plence P; Apparailly F; Noël D; Voide R; Pillon A; Nicolas JC; Müller R; Jorgensen C
    Bone; 2007 Apr; 40(4):1032-40. PubMed ID: 17251073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Marrow adipocyte-derived CXCL1 and CXCL2 contribute to osteolysis in metastatic prostate cancer.
    Hardaway AL; Herroon MK; Rajagurubandara E; Podgorski I
    Clin Exp Metastasis; 2015 Apr; 32(4):353-68. PubMed ID: 25802102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Theaflavin-3,3'-digallate represses osteoclastogenesis and prevents wear debris-induced osteolysis via suppression of ERK pathway.
    Hu X; Ping Z; Gan M; Tao Y; Wang L; Shi J; Wu X; Zhang W; Yang H; Xu Y; Wang Z; Geng D
    Acta Biomater; 2017 Jan; 48():479-488. PubMed ID: 27838465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Notch activation promotes bone metastasis via SPARC inhibition in adenoid cystic carcinoma.
    Zhang Y; Liu X; Zhu L; Zhou Z; Cui Y; Zhou CX; Li TJ
    Oral Dis; 2024 Apr; 30(3):1220-1233. PubMed ID: 36951790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone marrow-derived cathepsin K cleaves SPARC in bone metastasis.
    Podgorski I; Linebaugh BE; Koblinski JE; Rudy DL; Herroon MK; Olive MB; Sloane BF
    Am J Pathol; 2009 Sep; 175(3):1255-69. PubMed ID: 19700761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model.
    Ohno H; Kubo K; Murooka H; Kobayashi Y; Nishitoba T; Shibuya M; Yoneda T; Isoe T
    Mol Cancer Ther; 2006 Nov; 5(11):2634-43. PubMed ID: 17121910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p62/sequestosome 1 deficiency accelerates osteoclastogenesis
    Zach F; Polzer F; Mueller A; Gessner A
    J Biol Chem; 2018 Jun; 293(24):9530-9541. PubMed ID: 29555685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteoclastic miR-214 targets TRAF3 to contribute to osteolytic bone metastasis of breast cancer.
    Liu J; Li D; Dang L; Liang C; Guo B; Lu C; He X; Cheung HY; He B; Liu B; Li F; Lu J; Wang L; Shaikh AB; Jiang F; Lu C; Peng S; Zhang Z; Zhang BT; Pan X; Xiao L; Lu A; Zhang G
    Sci Rep; 2017 Jan; 7():40487. PubMed ID: 28071724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease.
    Bendre MS; Montague DC; Peery T; Akel NS; Gaddy D; Suva LJ
    Bone; 2003 Jul; 33(1):28-37. PubMed ID: 12919697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma.
    Michigami T; Ihara-Watanabe M; Yamazaki M; Ozono K
    Cancer Res; 2001 Feb; 61(4):1637-44. PubMed ID: 11245477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer.
    Goya M; Ishii G; Miyamoto S; Hasebe T; Nagai K; Yonou H; Hatano T; Ogawa Y; Ochiai A
    Prostate; 2006 Nov; 66(15):1573-84. PubMed ID: 16927388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption.
    Sasaki A; Alcalde RE; Nishiyama A; Lim DD; Mese H; Akedo H; Matsumura T
    Cancer Res; 1998 Feb; 58(3):462-7. PubMed ID: 9458090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.